Skip to content

US · CMPS · BIOTECHNOLOGY

COMPASS Pathways plc (CMPS) intrinsic value and stock valuation

$8.05as of 2026-11-21 · Mkt cap 1.83B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

COMPASS Pathways plc DCF and intrinsic value

InvestorsCraft values CMPS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CMPS’s statements →

COMPASS Pathways plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology London, CH W1F 0DQ compasspathways.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-287.86M
20182025
Free cash flow
-$-157.24M
20182025
Total equity
-$-52.85M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-179.04M-$-178.21M-$-136.92M-$-110.4M-$-83.22M
Net income-$-287.86M-$-155.12M-$-118.46M-$-91.5M-$-71.74M
EPSd-$-3.08M-$-2.3M-$-2.32M-$-2.16M-$-1.79M
Operating cash flow-$-157.24M-$-119.19M-$-97.38M-$-105.45M-$-67.75M
Capital expenditure$0.00$0.00-$-70K-$-600K-$-330K
Free cash flow-$-157.24M-$-119.19M-$-97.44M-$-106.05M-$-68.08M
Total assets$210.4M$213.7M$276M$197.3M$300.9M
Total debt$20.9M$32.2M$33.1M$1.93M$3.61M
Net debt-$-128.68M-$-132.89M-$-187.15M-$-141.28M-$-269.63M
Total equity-$-52.85M$154.7M$225.7M$181.3M$284.4M
Cash and short-term investments$149.6M$165.1M$220.2M$143.2M$273.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$118.4M$119M$87.5M$65.1M$44M
Selling, general and administrative expenses$60.6M$59.2M$49.4M$45.4M$39.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$179M$178.2M$136.9M$110.4M$83.2M
Cost and expenses$179M$178.2M$136.9M$110.4M$83.2M
Interest income$7.18M$8.27M$4.62M$0.00$0.00
Interest expense$4.52M$4.48M$2.2M$0.00$0.00
Depreciation and amortization$220K$230K$240K$330K$170K
Ebitda-$-285.6M-$-148.82M-$-115.24M-$-90.77M-$-71.37M
Operating income-$-179.04M-$-178.21M-$-136.92M-$-110.4M-$-83.22M
Total other income/expenses, net-$-111.3M$24.7M$19.2M$19.3M$11.7M
Income before tax-$-290.33M-$-153.53M-$-117.68M-$-91.1M-$-71.54M
Income tax expense-$-2.47M$1.59M$780K$410K$200K
Net income-$-287.86M-$-155.12M-$-118.46M-$-91.5M-$-71.74M
Weighted average shares outstanding$93.5M$67.5M$51M$42.4M$40M
Weighted average diluted shares outstanding$93.5M$67.5M$51M$42.4M$40M
Balance sheet
20252024202320222021
Cash and short-term investments$149.6M$165.1M$220.2M$143.2M$273.2M
Net receivables$15.4M$21.8M$28.9M$15.6M$11.2M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$191.5M$201.3M$261.3M$191.7M$295.3M
Property, plant and equipment, net$3.42M$2.19M$4.73M$2.62M$4.09M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$11M$470K$470K$470K$530K
Total non-current assets$18.9M$12.4M$14.7M$5.64M$5.6M
Total assets$210.4M$213.7M$276M$197.3M$300.9M
Accounts payable$15.2M$12.3M$5.89M$4.76M$2.56M
Short-term debt$19.6M$7.24M$2.41M$1.51M$2.23M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$247.8M$34M$19.6M$15.6M$15.1M
Long-term debt$1.29M$25M$30.6M$420K$1.38M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.4M$25M$30.6M$420K$1.38M
Capital lease obligations$0.00$2.03M$4.29M$1.93M$3.61M
Total liabilities$263.2M$59M$50.2M$16M$16.5M
Common stock$970K$700K$640K$440K$430K
Retained earnings-$-822.59M-$-534.73M-$-379.61M-$-261.15M-$-169.64M
Accumulated other comprehensive income (loss)-$-14.79M-$-16.19M-$-16.93M-$-16.87M$8.84M
Total equity-$-52.85M$154.7M$225.7M$181.3M$284.4M
Total investments$11M$470K$470K$470K$530K
Total debt$20.9M$32.2M$33.1M$1.93M$3.61M
Net debt-$-128.68M-$-132.89M-$-187.15M-$-141.28M-$-269.63M
Cash flow statement
20252024202320222021
Net income-$-287.86M-$-155.12M-$-118.46M-$-91.5M-$-71.74M
Depreciation and amortization$220K$230K$240K$330K$170K
Stock-based compensation$13.6M$19.5M$17.3M$13.1M$8.64M
Change in working capital-$-14.28M$11.7M$3.48M-$-30.67M-$-6.64M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.03M$6.59M$860K$2.5M-$-160K
Net cash provided by operating activities-$-157.24M-$-119.19M-$-97.38M-$-105.45M-$-67.75M
Investments in property, plant and equipment$0.00$0.00-$-70K-$-600K-$-330K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-60K-$-600K-$-330K
Common stock issued$141M$26.2M$144.9M$440K$154.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$140.7M$63.8M$173.8M$1.04M$156.7M
Net change in cash-$-15.48M-$-55.17M$77.3M-$-129.97M$83M
Cash at end of period$150M$165.5M$220.6M$143.4M$273.4M
Operating cash flow-$-157.24M-$-119.19M-$-97.38M-$-105.45M-$-67.75M
Capital expenditure$0.00$0.00-$-70K-$-600K-$-330K
Free cash flow-$-157.24M-$-119.19M-$-97.44M-$-106.05M-$-68.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About COMPASS Pathways plc

        COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

        CEO
        Kabir Kumar Nath
        Employees
        156
        Beta
        2.49

        Explore

        Frequently asked questions

        What is the intrinsic value of COMPASS Pathways plc (CMPS)?

        InvestorsCraft does not currently publish an intrinsic value for CMPS. How the IC value is calculated.

        Is CMPS undervalued?

        InvestorsCraft does not publish an undervaluation signal for CMPS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.